Fusion Antibodies plc (FAB.L), the provider of services for pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has warned that its FY24 H1 revenue is c. 23% below expectations at no less than £541k (vs £700k forecast). This reflects the weak trading environment and certain one-off delays associated with some contracts. Given that the investment case depends on a turnaround in trading – which is only just starting to materialise - we hav ....
